Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 19:11:1372434.
doi: 10.3389/fmed.2024.1372434. eCollection 2024.

Research advances in serum chitinase-3-like protein 1 in liver fibrosis

Affiliations
Review

Research advances in serum chitinase-3-like protein 1 in liver fibrosis

Xingwei Hu et al. Front Med (Lausanne). .

Abstract

While liver fibrosis remains a serious, progressive, chronic liver disease, and factors causing damage persist, liver fibrosis may develop into cirrhosis and liver cancer. However, short-term liver fibrosis is reversible. Therefore, an early diagnosis of liver fibrosis in the reversible transition phase is important for effective treatment of liver diseases. Chitinase-3-like protein 1 (CHI3L1), an inflammatory response factor that participates in various biological processes and is abundant in liver tissue, holds promise as a potential biomarker for liver diseases. Here, we aimed to review research developments regarding serum CHI3L1 in relation to the pathophysiology and diagnosis of liver fibrosis of various etiologies, providing a reference for the diagnosis, treatment, and prognosis of liver diseases.

Keywords: biomarker; chitinase-3-like protein 1; liver fibrosis; non-alcoholic fatty liver disease; viral hepatitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Biological functions of CHI3L1.

Similar articles

References

    1. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. (2017) 14:122–32. doi: 10.1038/nrgastro.2016.176 - DOI - PubMed
    1. Golabi P, Isakov V, Younossi ZM. Nonalcoholic fatty liver disease: disease burden and disease awareness. Clin Liver Dis. (2023) 27:173–86. doi: 10.1016/j.cld.2023.01.001 - DOI - PubMed
    1. Byass P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. (2014) 12:159. doi: 10.1186/s12916-014-0159-5, PMID: - DOI - PMC - PubMed
    1. Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol. (2003) 38:S38–53. doi: 10.1016/s0168-8278(02)00429-4 - DOI - PubMed
    1. Campana L, Iredale JP. Regression of liver fibrosis. Semin Liver Dis. (2017) 37:001–10. doi: 10.1055/s-0036-1597816 - DOI - PubMed